J. Ahnert

发表

Pan-cancer landscape and functional analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity

Hu, Shuai, Alexa, 2020 .

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).

R. Herbst, C. Fuchs, J. Bendell, 2017 .

PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).

J. Baselga, J. Tabernero, R. Dienstmann, 2012 .

Overview of Ocular Side Effect of Selinexor.

D. Gombos, A. Naing, D. Hong, 2021, The oncologist.

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

C. Cleeland, T. Mendoza, F. Meric-Bernstam, 2022, Scientific Reports.

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

F. Meric-Bernstam, T. George, S. Piha-Paul, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

R. Gray, S. Adams, R. Kurzrock, 2021, Clinical Cancer Research.

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

J. Ajani, C. Swanton, B. Czerniak, 2021, Nature Communications.

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

F. Meric-Bernstam, F. Janku, A. Naing, 2022, Scientific Reports.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, J. Heymach, 2019, Cancer cell.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Jing Wang, Kwok-Kin Wong, V. Miller, 2020, Cancer cell.

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

J. Baselga, J. Schellens, M. Schuler, 2012 .

A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.

J. Baselga, C. Britten, D. Demanse, 2012 .

A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.

P. Wen, T. Cloughesy, E. Gerstner, 2016 .

Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial

J. Lee, F. Meric-Bernstam, D. Kaya, 2021, Advances in Therapy.

A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.

J. Desai, D. Juric, J. Soria, 2014 .

A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.

J. Baselga, H. Tawbi, J. Dey, 2010 .

Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study

F. Meric-Bernstam, A. Naing, S. Piha-Paul, 2021, Investigational New Drugs.

Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.

F. Meric-Bernstam, K. Shaw, T. Yap, 2020 .

First-in-human study of LY3039478, a Notch signaling inhibitor in advanced or metastatic cancer.

J. Soria, C. Massard, C. Tourneau, 2015 .

Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.

F. Meric-Bernstam, F. Janku, A. Naing, 2019, Journal of Clinical Oncology.

Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC).

J. Machiels, L. Dirix, L. Paz-Ares, 2014 .

Erratum for the research article: mTORC1 inhibition is required forsensitivity to PI3K p110a inhibitors in PIK3CA-mutant breast cancer (Science Translational Medicine DOI: 10.1126/scitranslmed.3005747)

Manway Liu, J. Baselga, M. Mino‐Kenudson, 2018 .

Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.

F. Meric-Bernstam, S. Kopetz, F. Janku, 2020 .

The oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 plus lomustine in patients with treatment-refractory malignant glioma: The first human dose study.

J. Baselga, J. Seoane, M. Carducci, 2012 .

Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.

O. Rosen, M. Heinrich, M. von Mehren, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

A. El-Khoueiry, H. Mamdani, A. Spira, 2020 .

MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.

D. Ryan, W. Messersmith, T. Kalebic, 2014 .

Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors

A. Naing, S. Piha-Paul, B. Stephen, 2024, Cancer medicine.

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

L. C. Chen, J. Baselga, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.

O. Rosen, M. Heinrich, K. Ganjoo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

J. Baselga, D. Demanse, A. Razak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report

J. Ahnert, Camilla O Hoff, R. Ferrarotto, 2024, JCO precision oncology.

Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing

K. Patel, T. Yap, M. Daniels, 2023, Journal of immunotherapy and precision oncology.